ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AVO Advanced Oncotherapy Plc

1.925
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.925 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -29.49M -0.0549 -0.35 10.32M

Advanced Oncotherapy PLC Total Voting Rights (7712K)

30/08/2019 5:00pm

UK Regulatory


Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Advanced Oncotherapy Charts.

TIDMAVO

RNS Number : 7712K

Advanced Oncotherapy PLC

30 August 2019

30 August 2019

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Total Voting Rights

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company's issued share capital as at the date of this announcement comprises 230,226,094 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 230,226,094.

The above figure of 230,226,094 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 
  Advanced Oncotherapy Plc                                       www.avoplc.com 
  Dr. Michael Sinclair, Executive                         Tel: +44 20 3617 8728 
   Chairman 
  Nicolas Serandour, CEO 
 
  Allenby Capital Limited (Nomad 
   & Joint Broker) 
  Nick Athanas / Liz Kirchner /                           Tel: +44 20 7601 6100 
   Nicholas Chambers 
 
  Stifel Nicolaus Europe (Joint 
   Broker) 
  Jonathan Senior                                         Tel: +44 20 7710 7600 
 
  Walbrook PR (Financial PR & IR)   Tel: +44 20 7933 8780 or avo@walbrookpr.com 
  Paul McManus / Anna Dunphy                  Mob: +44 7980 54 1 893 / Mob: +44 
                                                                   7876 741 001 
 

About Advanced Oncotherapy Plc

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVREALPEDDXNEFF

(END) Dow Jones Newswires

August 30, 2019 12:00 ET (16:00 GMT)

1 Year Advanced Oncotherapy Chart

1 Year Advanced Oncotherapy Chart

1 Month Advanced Oncotherapy Chart

1 Month Advanced Oncotherapy Chart

Your Recent History

Delayed Upgrade Clock